A second-line degrader battle beckons
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
ASCO is fast approaching, but in the meantime Olema will have an important readout.
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.